{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:29:38Z","timestamp":1787506178025,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102008","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T17:26:59Z","timestamp":1581528419000},"page":"102008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?"],"prefix":"10.1016","volume":"41","author":[{"given":"Carla","family":"Prezioso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonella","family":"Zingaropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella Maria","family":"Rodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6338-2961","authenticated-orcid":false,"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Vullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosa","family":"Ciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Teresa","family":"Palamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5723-8886","authenticated-orcid":false,"given":"Valeria","family":"Pietropaolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102008_bib0001","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102008_bib0002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann. Neurol"},{"key":"10.1016\/j.msard.2020.102008_bib0003","unstructured":"Biogen. TYSABRI\u00ae (natalizumab): PML incidence in patients receiving TYSABRI. 2016. https:\/\/medinfo.biogen.com\/."},{"key":"10.1016\/j.msard.2020.102008_bib0004","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0733-8619(18)31105-8","article-title":"Progressive multifocal leukoencephalopathy","volume":"2","author":"Brooks","year":"1984","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2020.102008_bib0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/WNL.0000000000000768","article-title":"Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity","volume":"83","author":"Browne","year":"2014","journal-title":"Neurol."},{"key":"10.1016\/j.msard.2020.102008_bib0006","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa0904267","article-title":"Asymptomatic reactivation of JC virus in patients treated with natalizumab","volume":"361","author":"Chen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102008_bib0007","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/fvl-2019-0050","article-title":"An overview on human polyomaviruses biology and related diseases","volume":"14","author":"Ciotti","year":"2019","journal-title":"Future Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0008","doi-asserted-by":"crossref","first-page":"E940","DOI":"10.3390\/ijms18050940","article-title":"Natalizumab in multiple sclerosis: long-Term management","volume":"18","author":"Clerico","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2020.102008_bib0009","unstructured":"ClustalW2\u2013Multiple Sequence Alignment: http:\/\/www.ebi.ac.uk\/Tools\/msa\/clustalw2\/."},{"key":"10.1016\/j.msard.2020.102008_bib0010","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/jmv.21313","article-title":"Presence and expression of JCV early gene large T antigen in the brains of immunocompromised and immunocompetent individuals","volume":"80","author":"Delbue","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0011","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s13365-014-0268-0","article-title":"JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients","volume":"21","author":"Delbue","year":"2015","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2020.102008_bib0012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0042-6822(91)90069-N","article-title":"Amplification and sequencing of the control regions of BK and JC virus from human urine by polymerase chain reaction","volume":"180","author":"Flaegstad","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.msard.2020.102008_bib0013","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1590\/0004-282X20130121","article-title":"Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive","volume":"71","author":"Fragoso","year":"2013","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2020.102008_bib0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2017.07.011","article-title":"A brief history of NEDA","volume":"20","author":"Giovannoni","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102008_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102008_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/jmv.1890390110","article-title":"BK virus antigenic variants: sequence analysis within the capsid VP1 epitope","volume":"39","author":"Jin","year":"1993","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0017","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s007050170023","article-title":"New JC virus (JCV) genotypes from papua new guinea and micronesia (type 8 and type 2E) and evolutionary analysis of 32 complete JCV genomes","volume":"146","author":"Jobes","year":"2001","journal-title":"Arch. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0018","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102008_bib0019","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/bib\/bbn017","article-title":"MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences","volume":"9","author":"Kumar","year":"2008","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.msard.2020.102008_bib0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/(SICI)1096-9071(199607)49:3<199::AID-JMV7>3.0.CO;2-#","article-title":"Glial and muscle embryonal carcinoma cell-specific independent regulation of expression of human JC virus early promoter by cyclic amp response elements and adjacent nuclear factor 1 binding sites","volume":"49","author":"Kumar","year":"1996","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0021","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102008_bib0022","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMc1214233","article-title":"JC viremia in natalizumab-treated patients with multiple sclerosis","volume":"368","author":"Major","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102008_bib0023","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1474-4422(18)30040-1","article-title":"Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned","volume":"17","author":"Major","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2020.102008_bib0024","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1479-5876-10-248","article-title":"JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients","volume":"10","author":"Mancuso","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.msard.2020.102008_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/167.1.13","article-title":"Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and uninfected subjects","volume":"167","author":"Markowitz","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.msard.2020.102008_bib0026","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1099\/vir.0.035832-0","article-title":"JC virus promoter\/enhancers contain TATA box-associated Spi-B binding sites that support early viral gene expression in primary astrocytes","volume":"93","author":"Marshall","year":"2012","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0027","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","article-title":"Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy","volume":"1","author":"Padgett","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2020.102008_bib0028","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s13365-015-0338-y","article-title":"Human polyomavirus JC replication and noncoding control region analysis in multiple sclerosis patients under natalizumab treatment","volume":"21","author":"Pietropaolo","year":"2015","journal-title":"J. Neurovirol."},{"key":"10.1016\/j.msard.2020.102008_bib0029","first-page":"179","article-title":"John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy","volume":"41","author":"Pietropaolo","year":"2018","journal-title":"New Microbiol"},{"key":"10.1016\/j.msard.2020.102008_bib0030","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J, Med"},{"key":"10.1016\/j.msard.2020.102008_bib0031","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1007\/s00705-017-3542-7","article-title":"Efficient propagation of archetype JC polyomavirus in COS-7 cells: evaluation of rearrangements within the NCCR structural organization after transfection","volume":"162","author":"Prezioso","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12985-018-0939-1","article-title":"COS-7-based model: methodological approach to study John Cunningham virus replication cycle","volume":"15","author":"Prezioso","year":"2018","journal-title":"Virol. J."},{"key":"10.1016\/j.msard.2020.102008_bib0033","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcv.2013.03.009","article-title":"Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variants","volume":"57","author":"Ryschkewitsch","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000368","article-title":"Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML)","volume":"5","author":"Sunyaev","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.msard.2020.102008_bib0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis \u2013 success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.102008_bib0036","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102008_bib0037","doi-asserted-by":"crossref","first-page":"10846","DOI":"10.1128\/JVI.00542-09","article-title":"Regulation of gene expression in primate polyomaviruses","volume":"83","author":"White","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.msard.2020.102008_bib0038","doi-asserted-by":"crossref","first-page":"i3518","DOI":"10.1136\/bmj.i3518","article-title":"Disease modifying therapies for relapsing multiple sclerosis","volume":"354","author":"Wingerchuk","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2020.102008_bib0040","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1128\/jvi.64.6.3139-3143.1990","article-title":"Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals","volume":"64","author":"Yogo","year":"1990","journal-title":"J. Virol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:48:14Z","timestamp":1761900494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820300845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":39,"alternative-id":["S2211034820300845"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102008","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102008"}}